Skip to main content

COVID-19 Topic Center

Migraine News

News
Decreases in migraine frequency as well as severity were the most meaningful outcome measures of a migraine medication’s value as judged by patients, providers, and other stakeholders, according to a study published online in Headache: The Journal of Head and Face Pain. “Value‐based contracts…
News
Eli Lilly announced that its new acute migraine treatment, Reyvow (lasmiditan), will be priced at $640 for a pack of eight pills. Migraine is typically treated using triptans, but Reyvow is the first and only FDA-approved ditan, 5-HT1F receptor agonist, believed to act both centrally and…
News
According to recent research presented at the AMCP Annual Meeting 2019, opioid use is common among migraine patients using prescription medication. Further, increased opioid use among this patient population leads to worsened health, including elevated body mass index, cardiovascular comorbidities…
News
Researchers recently found that patient reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis.  “[CGRP] antagonists are a new drug class indicated for…
News
Aerobic exercise appears to reduce the number of days patients experience migraine, according to a systematic literature review and meta-analysis published in The Journal of Headache Pain. The review included six studies published over the last 15 years involving a total 357 patients with migraine…
News
The new class of calcitonin gene-related peptide (CGRP) inhibitors for migraine relief appear to represent a major evolution in migraine therapy, but high costs may hinder patient access to the biologics, according to a paper in The American Journal of Managed Care. Anticipating this,…
News
Direct, indirect, and societal costs were all significantly higher among patients with migraine compared with patients without migraine, according to a recent study in the Journal of Occupational and Environmental Medicine. For the study, researchers used MarketScan claims and Health and…
News
Noninvasive vagus nerve stimulation using gammaCore, in addition to standard of care for acute treatment of migraine, is more cost-effective for payers compared with standard of care alone, according to an analysis published in The American Journal of Managed Care. “GammaCore is used adjunctively…
Newsfeed
US adults with obesity had more than $2000 in health expenses annually when they also reported migraine, according to a study in ClinicoEconomics and Outcomes Research. Researchers used the Household Component of the Medical Expenditure Panel Survey to identify 23,596 adults with obesity, of whom…
Newsfeed
Employers aiming to shift high drug costs to employees through prescription plans with multiple drug tiers do themselves and their workers a disservice, suggested a column published online in Health Affairs. With increasing levels of cost sharing, such plans may encourage employees to skip doses…
Back to Top